ES2097703B1 - Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion. - Google Patents

Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion.

Info

Publication number
ES2097703B1
ES2097703B1 ES09500739A ES9500739A ES2097703B1 ES 2097703 B1 ES2097703 B1 ES 2097703B1 ES 09500739 A ES09500739 A ES 09500739A ES 9500739 A ES9500739 A ES 9500739A ES 2097703 B1 ES2097703 B1 ES 2097703B1
Authority
ES
Spain
Prior art keywords
eburnamenine
alkaloids
nucleus
alcaloids
brain activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES09500739A
Other languages
English (en)
Other versions
ES2097703A1 (es
Inventor
Consuelo Lazaro
Paula Calvo
Elena Calvo
Teresa Manresa
Fernando Calvo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Decox SL
Original Assignee
Decox SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES09500739A priority Critical patent/ES2097703B1/es
Application filed by Decox SL filed Critical Decox SL
Priority to HU9603272A priority patent/HU225463B1/hu
Priority to DE69635257T priority patent/DE69635257D1/de
Priority to EA199600105A priority patent/EA000189B1/ru
Priority to MX9606217A priority patent/MX9606217A/es
Priority to EP96909178A priority patent/EP0760240B1/en
Priority to NZ304889A priority patent/NZ304889A/xx
Priority to PCT/ES1996/000082 priority patent/WO1996032113A1/es
Priority to JP8530733A priority patent/JPH10501558A/ja
Priority to AT96909178T priority patent/ATE306268T1/de
Priority to CA002192438A priority patent/CA2192438C/en
Priority to PL96317647A priority patent/PL185056B1/pl
Priority to CNB961905913A priority patent/CN1161122C/zh
Priority to AU52769/96A priority patent/AU719877B2/en
Priority to BR9606302A priority patent/BR9606302A/pt
Priority to NO19965303A priority patent/NO313536B1/no
Publication of ES2097703A1 publication Critical patent/ES2097703A1/es
Publication of ES2097703B1 publication Critical patent/ES2097703B1/es
Application granted granted Critical
Priority to US09/654,332 priority patent/US6290994B1/en
Priority to JP2007247938A priority patent/JP2008056681A/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/56—Cocoa products, e.g. chocolate; Substitutes therefor making liquid products, e.g. for making chocolate milk drinks and the products for their preparation, pastes for spreading, milk crumb
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
    • A23F3/30—Further treatment of dried tea extract; Preparations produced thereby, e.g. instant tea
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F5/00—Coffee; Coffee substitutes; Preparations thereof
    • A23F5/24—Extraction of coffee; Coffee extracts; Making instant coffee
    • A23F5/36—Further treatment of dried coffee extract; Preparations produced thereby, e.g. instant coffee
    • A23F5/40—Further treatment of dried coffee extract; Preparations produced thereby, e.g. instant coffee using organic additives, e.g. milk, sugar
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G2200/00—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G2200/00—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
    • A23G2200/14—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents containing fruits, nuts, e.g. almonds, seeds, plants, plant extracts or essential oils

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Steroid Compounds (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UNA NUEVA COMPOSICION ESTIMULANTE DE LA ACTIVIDAD CEREBRAL BASADA EN ALCALOIDES DE NUCLEO DE EBURNAMENINA, Y SUS METODOS DE PREPARACION. LA PRESENTE INVENCION SE BASA EN EL DESCUBRIMIENTO DE LA POTENTE ACCION QUE PRESENTAN CIERTOS ALCALOIDES DE NUCLEO DE EBURNAMENINA CUANDO SE ADMINISTRAN CONJUNTAMENTE CON COMPUESTOS DE ESTRUCTURA DE XANTINA. SE OBTIENE UNA POTENTE ACCION SINERGICA EN LA CAPACIDAD COGNOSCITIVA Y POR TANTO, LA ACTIVIDAD CEREBRAL SE VE REFORZADA EN GENERAL A CORTO Y LARGO PLAZO TRAS LA ADMINISTRACION ORAL DE LA COMPOSICION QUE SE PATENTA. LA COMPOSICION QUE SE PATENTA CONTIENE CANTIDADES COMPRENDIDAS ENTRE 0,5 Y 10YMG DE ALCALOIDES O EXTRACTO DE ALCALOIDES DEL TIPO EBURNAMENINA POR CADA 100YML DE BEBIDA DE COLA, LIMON, CACAO, GINSENG, AGUA TONICA, CAFE, O CUALQUIER OTRA BEBIDA A PARTIR DE EXTRACTOS, Y CANTIDADES COMPRENDIDAS ENTRE 0,5 Y 30YMG DE ALCALOIDES O EXTRACTO DE ALCALOIDES DEL TIPO EBURNAMENINA POR CADA 5-20YG DE EXTRACTO SECO, SEMISECO O HUMEDO DE CAFE, COLA, CACAO,TE, GINSENG DE TONICA O CUALQUIER OTRO EXTRACTO PARA BEBIDA.
ES09500739A 1995-04-12 1995-04-12 Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion. Expired - Fee Related ES2097703B1 (es)

Priority Applications (18)

Application Number Priority Date Filing Date Title
ES09500739A ES2097703B1 (es) 1995-04-12 1995-04-12 Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion.
CNB961905913A CN1161122C (zh) 1995-04-12 1996-04-10 基于具有象牙烯宁核的生物碱的刺激大脑活动的新组合物及其制备方法
DE69635257T DE69635257D1 (de) 1995-04-12 1996-04-10 Zusammensetzung enthaltend Vinpocetin-Citrat und einen Xanthin-enthaltenden Pflanzenextrakt zur Stimulierung der Gerhirnaktivität
MX9606217A MX9606217A (es) 1995-04-12 1996-04-10 Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion.
EP96909178A EP0760240B1 (en) 1995-04-12 1996-04-10 Composition for stimulating the cerebral activity comprising vinpocetine citrate and a plant extract comprising xanthines
NZ304889A NZ304889A (en) 1995-04-12 1996-04-10 Oral composition, which stimulates cerebral activity, containing alkaloids of the eburnamenine type and xanthine bases containing plant extracts
PCT/ES1996/000082 WO1996032113A1 (es) 1995-04-12 1996-04-10 Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preraracion
JP8530733A JPH10501558A (ja) 1995-04-12 1996-04-10 エブルナメニン核のアルカロイドを主原料とする大脳活動を刺激する新しい組成物及びその調製法
AU52769/96A AU719877B2 (en) 1995-04-12 1996-04-10 A new composition which stimulates cerebral activity, based upon alkaloids with an eburnamenine nucleus, and methods for their preparation
CA002192438A CA2192438C (en) 1995-04-12 1996-04-10 Novel composition stimulating the cerebral activity and based on alkaloids having an eburnamenine nucleus, and preparation methods
HU9603272A HU225463B1 (en) 1995-04-12 1996-04-10 An oral composition enhancing brain's activity
EA199600105A EA000189B1 (ru) 1995-04-12 1996-04-10 Композиция на основе алкалоидов эбурнаменинового типа, стимулирующая церебральную активность
AT96909178T ATE306268T1 (de) 1995-04-12 1996-04-10 Zusammensetzung enthaltend vinpocetin-citrat und einen xanthin-enthaltenden pflanzenextrakt zur stimulierung der gerhirnaktivität
BR9606302A BR9606302A (pt) 1995-04-12 1996-04-10 Composição estimulante da atividade cerebral para uso oral
PL96317647A PL185056B1 (pl) 1995-04-12 1996-04-10 Kompozycja do podawania doustnego
NO19965303A NO313536B1 (no) 1995-04-12 1996-12-11 Nytt preparat som stimulerer den cerebrale aktivitet og basert pa alkaloider som har en eburnameninkjerne
US09/654,332 US6290994B1 (en) 1995-04-12 2000-09-01 Beverage containing caffeine or theobromine and vinpocetine citrate for stimulating cerebral activity
JP2007247938A JP2008056681A (ja) 1995-04-12 2007-09-25 エブルナメニン核のアルカロイドを主原料とする大脳活動を刺激する新しい組成物及びその調製法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09500739A ES2097703B1 (es) 1995-04-12 1995-04-12 Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion.

Publications (2)

Publication Number Publication Date
ES2097703A1 ES2097703A1 (es) 1997-04-01
ES2097703B1 true ES2097703B1 (es) 1997-12-01

Family

ID=8290094

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09500739A Expired - Fee Related ES2097703B1 (es) 1995-04-12 1995-04-12 Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion.

Country Status (17)

Country Link
US (1) US6290994B1 (es)
EP (1) EP0760240B1 (es)
JP (2) JPH10501558A (es)
CN (1) CN1161122C (es)
AT (1) ATE306268T1 (es)
AU (1) AU719877B2 (es)
BR (1) BR9606302A (es)
CA (1) CA2192438C (es)
DE (1) DE69635257D1 (es)
EA (1) EA000189B1 (es)
ES (1) ES2097703B1 (es)
HU (1) HU225463B1 (es)
MX (1) MX9606217A (es)
NO (1) NO313536B1 (es)
NZ (1) NZ304889A (es)
PL (1) PL185056B1 (es)
WO (1) WO1996032113A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2115561B1 (es) * 1996-12-10 1999-02-16 L B N Lab S L Composicion energetica para uso alimentario.
US6228418B1 (en) * 1999-04-07 2001-05-08 Cyvex Nutrition Vegetarian pet treat
US8153646B2 (en) * 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
DK1355669T3 (da) * 2000-08-10 2011-11-21 Cold Spring Harbor Lab Forbedret kognitiv træning
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
US7207263B2 (en) * 2003-01-21 2007-04-24 Frito-Lay North America, Inc. Single mold form fryer with product centering elements
US7429565B2 (en) 2003-04-25 2008-09-30 Gilead Sciences, Inc. Antiviral phosphonate analogs
EP1744732A4 (en) * 2004-05-07 2009-08-26 Thermo Formulations Ltd NUTRITIONAL COMPOSITION FOR INCREASING CREATINE IN A SKELETON MUSCLE
SI2258376T1 (sl) 2004-07-27 2019-04-30 Gilead Sciences, Inc. Analogi fosfonata spojin inhibitorjev HIV
US20060051461A1 (en) * 2004-09-03 2006-03-09 Jose Antonio Nutrified coffee compositions
US20080044522A1 (en) * 2004-09-03 2008-02-21 Jose Antonio Nutrified coffee compositions
US20080003278A1 (en) * 2006-06-28 2008-01-03 Fernando Calvo Mondelo Food products and dietary supplements for improving mental performance
JP2008017734A (ja) * 2006-07-11 2008-01-31 Memory Secret Inc 精神的機能を改善するための栄養補助及び栄養摂取食品用の口経投与組成物
US8046976B2 (en) * 2006-07-25 2011-11-01 The Coca-Cola Company Devices and methods for packaging beverages
EP2307435B1 (en) 2008-07-08 2012-06-13 Gilead Sciences, Inc. Salts of hiv inhibitor compounds
NZ611965A (en) * 2008-12-01 2015-01-30 Targacept Inc Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
EP2206438B1 (en) * 2008-12-29 2012-02-08 Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House Frozen confectionery and beverage products comprising theobromine and caffeine
CA2798911C (en) 2010-05-19 2018-07-03 Unilever Plc Theobromine for increasing hdl-cholesterol
CN104382846A (zh) * 2014-10-27 2015-03-04 威海爱威制药有限公司 长春西汀葡萄糖注射液及其制备方法
EP3777861A1 (en) * 2015-08-01 2021-02-17 Sun Pharmaceutical Industries Ltd Dosage form of vinca alkaloid drug
CN105153147A (zh) * 2015-08-04 2015-12-16 江苏正大清江制药有限公司 一种长春西汀与磷酸形成的盐的晶型及制备方法
US11124506B2 (en) * 2016-08-04 2021-09-21 Harbin Pharmaceutical Group Co., Ltd. General Pharmaceutical Factory Salts and crystal forms of diaza-benzofluoranthrene compounds
IT201700025286A1 (it) * 2017-03-07 2018-09-07 Linnea Sa Forme cristalline di vinpocetina cloridrato
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2193587A1 (en) * 1972-07-31 1974-02-22 Centre Etd Ind Pharma Vincamine lauryl sulphate compsns - for humans and animals, as a cerebral and coronary vasodilator, without bitter taste
FR2193586A1 (en) * 1972-07-31 1974-02-22 Centre Etd Ind Pharma Vincamine dioctyl sulphosuccinate for medical use - for humans and animals as a cerebral and coronary vasodilator, with no bitter taste
FR2255890B1 (es) 1973-12-28 1978-01-13 Centre Etd Ind Pharma
ES430063A1 (es) * 1974-09-14 1976-10-01 Corbera Gubern Procedimiento para la obtencion de una sal del acido alfa- cetoglutarico.
FR2319362A1 (fr) * 1975-07-31 1977-02-25 Parcor Medicament a base de substances possedant le squelette de l'eburnane
DE2559384A1 (de) 1975-12-31 1977-07-14 Josef Dipl Chem Dr Rer N Klosa Coffein-kombination
DE2962239D1 (en) 1978-10-18 1982-04-01 Tate & Lyle Patent Holdings A method for the preparation of 2-chloro-2-deoxy saccharides and some 2-chloro-2-deoxy saccharides
US4362730A (en) * 1980-08-25 1982-12-07 Heinrich Mack Nachf. Chem-Pharm. Fabrik Vincamine saccharinate and a pharmaceutical composition containing it dissolved therein
DE3479423D1 (en) 1984-02-29 1989-09-21 Covex Sa Citrate of vinpocetine, and process for its preparation
ES8505677A1 (es) * 1984-05-10 1985-06-16 Covex Sa Procedimiento para la preparacion del citrato de la (+) vinpocetina
US4966893A (en) 1989-01-13 1990-10-30 Pang Peter K T Method for treatment of senile dementia
IT1236649B (it) 1989-11-03 1993-03-25 Nuovo Pignone Spa Sistema perfezionato di azionamento a nastro della pinza portatrama per un telaio tessile senza navetta.
US5571441A (en) 1994-11-01 1996-11-05 The Procter & Gamble Company Nutrient supplement compositions providing physiologic feedback

Also Published As

Publication number Publication date
AU719877B2 (en) 2000-05-18
BR9606302A (pt) 1997-11-18
CA2192438A1 (en) 1996-10-17
NO965303L (no) 1997-01-28
NZ304889A (en) 1999-02-25
PL317647A1 (en) 1997-04-14
WO1996032113A1 (es) 1996-10-17
HU225463B1 (en) 2006-12-28
MX9606217A (es) 1998-03-31
DE69635257D1 (de) 2006-02-23
HUP9603272A3 (en) 2000-07-28
JP2008056681A (ja) 2008-03-13
NO965303D0 (no) 1996-12-11
EA199600105A1 (ru) 1997-09-30
HUP9603272A2 (hu) 2000-04-28
JPH10501558A (ja) 1998-02-10
ES2097703A1 (es) 1997-04-01
EP0760240A1 (en) 1997-03-05
PL185056B1 (pl) 2003-02-28
US6290994B1 (en) 2001-09-18
CN1161122C (zh) 2004-08-11
CA2192438C (en) 2009-03-17
NO313536B1 (no) 2002-10-21
AU5276996A (en) 1996-10-30
EP0760240B1 (en) 2005-10-12
EA000189B1 (ru) 1998-12-24
ATE306268T1 (de) 2005-10-15
CN1155842A (zh) 1997-07-30

Similar Documents

Publication Publication Date Title
ES2097703B1 (es) Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion.
Feder Bradycardia and syncope induced by fluoxetine.
Ross et al. Dissociative experiences in adolescents and college students.
ES2173420T3 (es) Comprimidos que contienen un antibiotico de beta-lactamico y procedimiento para su produccion.
AR003989A1 (es) Composicion cosmetica o farmaceutica y procedimiento de tratamiento cosmetico, excluido tdo tratamiento terapeutico que utiliza la composicion cosmetica.
ES2037086T3 (es) Procedimiento para preparar formulaciones farmaceuticas.
BR9916887A (pt) Uso de derivados de pirimidina
Fawcett et al. Fluoxetine versus amitriptyline in adult outpatients with major depression.
Bracco et al. Lateralization of choline acetyltransferase (ChAT) activity in fetus and adult human brain
Whelpton et al. Bioavailability of oral physostigmine.
Harbison Clinical considerations in selecting antiplatelet therapy in cerebrovascular disease
Meco et al. Risperidone in Huntington's disease.
KR960040370A (ko) 알콜 장해 예방 및 치료제 조성물
Garner Sodium nitroprusside treatment in patients with acute strokes
Summers et al. " Use of THA in treatment of Alzheimer-like dementia: Pilot study in twelve patients": Reply.
USD230970S (en) Passenger vehicle
USD221340S (en) Book support for holding a book in open position
de Wilde et al. The antidepressive effect of zimelidine and doxepin in endogenous depression: A double blind study.
USD123226S (en) Front car of a railway train
USD224657S (en) Combined golf ball marker and holder
RU96108458A (ru) Способ лечения заболеваний центральной нервной системы
Shimizu et al. Effects of ozone administration on cerebral and hepatic tissue metabolism in hemorrhagic shock
Landes STUDIES ON THE EFFECTS OF SEVERAL VASOACTIVE AGENTS ON THE BLOOD-CSF BARRIER TO POTASSIUM ION
Ledo et al. Doxepin in the treatment of chronic urticaria
Hanna et al. Erratum to “Impaired mitochondrial translation in human myoblasts harbouring the mitochondrial DNA tRNA lysine 8344 A→ G (MERRF) mutation: relationship to proportion of mutant mitochondrial DNA”: J. Neurol. Sci. 130 (1995) 154–160

Legal Events

Date Code Title Description
PC2A Transfer of patent

Owner name: DECOX, S.A.

EC2A Search report published

Date of ref document: 19970401

Kind code of ref document: A1

Effective date: 19970401

FD2A Announcement of lapse in spain

Effective date: 20150826